Literature DB >> 15282442

Cardiovascular complications in acromegaly.

G Vitale1, R Pivonello, G Lombardi, A Colao.   

Abstract

Cardiovascular morbidity and mortality are increased in acromegaly. In fact, GH and IGF-I excess induces a specific cardiomyopathy. The early stage of acromegaly is characterized by the hyperkinetic syndrome (high heart rate and increased systolic output). Frequently, concentric biventricular hypertrophy and diastolic dysfunction occur in acromegaly, leading to an impaired systolic function ending in heart failure if the disease is untreated or unsuccessfully untreated. Besides, abnormalities of cardiac rhythm and of valves have been also described in acromegaly. The coexistence of other complications, such as arterial hypertension and diabetes, aggravates the acromegalic cardiomyopathy. The suppression of GH/IGF-I following an efficacious therapy could decrease left ventricular mass and improve cardiac function. In conclusion, a careful evaluation of cardiac function, morphology and activity seems to be mandatory in acromegaly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282442

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  9 in total

1.  Procalcitonin can be used as a marker of premature atherosclerosis in acromegaly.

Authors:  H Ozkan; O Celik; E Hatipoglu; F Kantarci; P Kadioglu
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Left ventricular 'rigid body rotation' in a patient with acromegaly (from the MAGYAR-Path Study).

Authors:  Attila Nemes; Árpád Kormányos; Péter Domsik; Anita Kalapos; Csaba Lengyel; Zsuzsanna Valkusz; Tamás Forster
Journal:  Quant Imaging Med Surg       Date:  2017-06

Review 3.  Illicit use of androgens and other hormones: recent advances.

Authors:  Gen Kanayama; Harrison G Pope
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-06       Impact factor: 3.243

4.  Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.

Authors:  Brian J Potter; Catherine Beauregard; Omar Serri
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

5.  Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly.

Authors:  Muhammet Dural; Giray Kabakcı; Neşe Cınar; Tomris Erbaş; Uğur Canpolat; Kadri Murat Gürses; Lale Tokgözoğlu; Ali Oto; Ergün Barış Kaya; Hikmet Yorgun; Levent Sahiner; Selçuk Dağdelen; Kudret Aytemir
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

6.  Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.

Authors:  Cihangir Erem; Irfan Nuhoglu; Mustafa Kocak; Mustafa Yilmaz; Safiye Tuba Sipahi; Ozge Ucuncu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

7.  Prescription patterns of long-acting somatostatin analogues.

Authors:  Jorge Enrique Machado-Alba; Manuel Enrique Machado-Duque
Journal:  SAGE Open Med       Date:  2017-03-09

Review 8.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

9.  Leptin Receptor Gene Polymorphism may Affect Subclinical Atherosclerosis in Patients with Acromegaly.

Authors:  Sebahat Turgut; Senay Topsakal; Melek Tunç Ata; Duygu Herek; Fulya Akın; Şeyma Özkan; Günfer Turgut
Journal:  Avicenna J Med Biotechnol       Date:  2016 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.